Synchron, maker of an endovascular brain-computer interface (BCI), has tapped Kurt Haggstrom as chief commercial officer. In that role, Haggstrom will oversee the company’s commercial organization, including marketing and reimbursement.
Synchron recently announced the company will launch clinical trials for the first-ever BCI implant in the U.S. “Kurt joins us at a crucial moment in our development, on the heels of successful clinical results in our Australia trial, and commencement of our U.S. trial,” said Synchron CEO Tom Oxley in a statement.
